Sanctuary Advisors LLC Buys Shares of 291,759 Novo Nordisk A/S (NYSE:NVO)

Sanctuary Advisors LLC bought a new stake in shares of Novo Nordisk A/S (NYSE:NVO) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 291,759 shares of the company’s stock, valued at approximately $41,646,000.

Other institutional investors have also modified their holdings of the company. Creekside Partners acquired a new stake in Novo Nordisk A/S in the second quarter worth about $215,000. Gordian Capital Singapore Pte Ltd lifted its holdings in Novo Nordisk A/S by 42.0% in the 2nd quarter. Gordian Capital Singapore Pte Ltd now owns 7,100 shares of the company’s stock valued at $1,013,000 after acquiring an additional 2,100 shares during the last quarter. Strategic Investment Solutions Inc. IL acquired a new stake in Novo Nordisk A/S in the 2nd quarter valued at about $25,000. Souders Financial Advisors lifted its stake in Novo Nordisk A/S by 0.6% during the second quarter. Souders Financial Advisors now owns 39,696 shares of the company’s stock valued at $5,666,000 after buying an additional 230 shares in the last quarter. Finally, Dana Investment Advisors Inc. lifted its stake in Novo Nordisk A/S by 1.0% during the second quarter. Dana Investment Advisors Inc. now owns 20,984 shares of the company’s stock valued at $2,995,000 after buying an additional 208 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Monday, September 16th. BMO Capital Markets dropped their price objective on Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Finally, Argus increased their price target on Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a report on Monday, June 10th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Buy” and a consensus price target of $145.17.

Novo Nordisk A/S Stock Down 0.9 %

Shares of NVO stock opened at $117.95 on Wednesday. The stock has a market cap of $529.30 billion, a P/E ratio of 40.67, a price-to-earnings-growth ratio of 1.35 and a beta of 0.42. Novo Nordisk A/S has a one year low of $86.96 and a one year high of $148.15. The stock has a fifty day moving average price of $131.38 and a 200 day moving average price of $132.77. The company has a debt-to-equity ratio of 0.46, a current ratio of 0.94 and a quick ratio of 0.75.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, August 7th. The company reported $0.65 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.71 by ($0.06). Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. The company had revenue of $9.82 billion for the quarter, compared to analyst estimates of $9.91 billion. Analysts predict that Novo Nordisk A/S will post 3.11 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 16th were paid a dividend of $0.5126 per share. The ex-dividend date was Friday, August 16th. This represents a yield of 0.7%. Novo Nordisk A/S’s dividend payout ratio is currently 24.83%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.